Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia by Munclinger, M.J. et al.
ORIGINAL ARTICLES
effective, high-quality and affordable ambulatory health
services for patients with chronic diseases at primary,
secondary and tertiary levels.
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Miroslav J Mundinger, Jai J Patel, Abdul 5 Mitha
Objective. The enlargement of data on the natural course and
management of patients with arrhythmogenic right
ventricular cardiomyopathy / dysplasia (ARVC/D).
Design. Retrospective and partly prospective observational
study.
Setting. Cardiac Unit, Wentworth Hospital, Durban - the
only unit in KwaZulu-Natal providing an arrhythmia and
electrophysiology service.
Study papulation. Those included were: (i) patients referred for
palpitations, unexplained syncope, or ventricular tachycardia
and in whom ARVC/D was diagnosed according to multiple
criteria; and (ii) family members of patients with ARVC/D in
whom the disease was documented using the same criteria.
Main outcome and measurements. Diagnosis, management,
morbidity and mortality were analysed.
Results. Twelve patients were diagnosed with ARVC/D over
a period or 6 years. At the end of follow-up for 3.4 ± 3.2
years, 7 of them were well and alive on anti-arrhythmic
medication, 2 were asymptomatic, and 3 had died. One death
was sudden, 1 patient died due to left ventricular failure, and
1 patient died due to a low cardiac output syndrome 3
months after right ventricular isolation, i.e. the mortality rate
was 25%. ARVC/D was found in all racial groups and was
familial in 5 patients (42%). In all but one patient the correct
diagnosis was not suspected by the referring institution,
physician or cardiologist..
Conclusions. ARVC/D needs to be included into a differential
diagnosis of unexplained syncope, palpitations, or ventricular
tachycardia by an health service providers. Its management
remains a complex challenge with varying results.
s Afr Med J 2IXXJ; 90: 61-68.
Cardiac Unit, Wentwortlt Hospital and University of Natal, Durban
Miroslav J Munclinger, MD, PhD
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Arrhythmogenic right ventricular cardiomyopathy / dysplasia
(ARVC/D)l was defined as a syndrome in 1978;' however, data
analysing the broad clinical spectrum of this disease and
assessing different therapeutic modalities are still incomplete.
Twenty years later general awareness of the disease has not
spread satisfactorily and appropriate diagnosis and
management has often been offered only to those patients who
reach centres specialised in the management and treatment of
rhythm disturbances.
The disease is characterised by a replacement of the
myocardium of the right ventricle with fibrofatty tissue. The
coexistence of fibrofatty tissue and surviving myocardium
creates an environment for ventricular arrhythrnias. It is an
important cause of unexpected :::dd;::; '::r"i~ l 2ffil'''g ~""'ng
people, especially competitive athletes.'
ARVC/D has been reported in America, Europe, and Asia....
Cases diagnosed and followed up at Wentworth Hospital,
Durban within the last 6 years are reported here to complement
existing data on the geographical distribution of ARVC/D and
to enlarge the limited pool of data on clinical course and
follow-up of patients afflicted with this condition.
PATIENTS AND METHODS
Patients were diagnosed as having ARVC/D according to
criteria suggested recently.' These criteria are based on
structural abnormalities of the right ventricle, tissue
characterisation of the right ventricle, electrocardiographic
criteria, and family history. The presence of two major, one
major and two minor, or four minor criteria is considered to be
diagnostic.'
Patients were followed up in a general cardiology clinic, or
later in a clinic focused on arrhythrnias. The follow-up periods
differed according to clinical needs but were a minimum of 1
year for all patients, with the exception of one patient (SC) who
defaulted for 10 years. Standard facilities and methods were
used for routine examinations. Signal-averaged ECG was done
using software available in MAC15 (Marquette Electronics 1nc).
Echocardiographic examinations were done using a variety of
equipment; in recent years they have been performed with
Hewlett Packard Sonos 2500.
All angiograpruc investigations as well as biopsies were done
via femoral access. A Mullins transseptal sheath was used for
the manipulation of the bioptom in the right ventricle. Multiple
sites were targeted and samples were routinely taken from the
apical area of the right ventricle. The ventricular stimulation
protocol used during electrophysiological studies involved
drives of eight extrastimuli followed by up to three
independently timed extrastimuli and bursts of fast ventricular
pacing, both in the resting state and while on isoprenaline.
Radiofrequency catheter ablation was attempted using
catheters and ablators from Medtronic and EP Technologies.
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Magnetic resonance irnaging (MRl) was performed using either
a Siemens 1.0 Tesla (St Aiden's Hospital, Durban) or a General
Electric 1.5 Tesla (Wentworth Hospital, Durban). Right
ventricular isolation in patient CK was performed by Professor
U von Oppell at Groote Schuur Hospital, Cape Town.
Pharmacological treatment was empirically instituted in
symptomatic patients. Tolerated ventricular ectopia has been
considered 'acceptable', but if a recurrence of sustained
ventricular tachycardia or frequent and symptomatic episodes
of non-sustained ventricular tachycardias occurred, tJ;len the
drug dose was either increased or the drug was changed.
Electrophysiological studies were used to document ventricular
tachycardia in patients without 12-lead ECG of clinical
tarhycardi;> "no in some patients with infrequent episodes of
ventricular tachycardia in order to assess the drug effect.'
RESULTS
Diagnosis of ARVC/D
Over the last 6 years 12 patients were diagnosed as having
ARVC/D. The diagnostic features used for the final diagnosis
are summarised in Table 1. Eight patients were white, 2 were
black and 2 were of Asian descent. Two of them were
asymptomatic and were diagnosed only because of familial
occurrence. The most frequent symptom was palpitations. As
an index symptom syncope was observed in 2 patients (Table
IT). Spontaneous sustained or non-sustained ventricular
tachycardias were documented in 9 patients and were
inducible in all but 1 of the patients submitted to an
electrophysiological study. More than one morphology of
ventricular premature contractions (VPCs) or ventricular
tachycardia were observed in 8 patients. None of our patients
had clinical signs of right-sided congestive failure, but both
patients who had clinical signs of left ventricular failure died
(1 after arrhythmia surgery).
Follow-up
Patients were followed up for 3.4 ± 3.2 (0.5 - 12.8) years. All
symptomatic patients were on anti-arrhythmic drugs (Table III).
The majority of patients had tried various drugs over the years,
but eventually stayed on arniodarone. Sotalol was usually
attempted before amiodarone was started. The sudden death of
patient LW was probably caused by a pro-arrhythmic effect of
propafenone.
Catheter ablation was attempted twice in patient NL.
Although ventricular stimulation induced two different
morphologies of ventricular tachycardia, ablation of clinically
relevant exercise-induced tachycardia originating in the right
yentricular outflow tract was attempted. This tachycardia
exited at the antero-septal aspect of the basal right ventricular
outflow tract, i.e. in the area where we normally ablate
idiopathic right ventricular outflow tract tachycardias, and its
..
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Table 1. Di.agnosis of arrhythmogenic right ventricular dysplasia
Patient Sbuctural RV abnormalities TIssue characteristics ECG Anhythrrrias SAECG Familial Criteria
se A: global dilatation B: not performed Epsilon wave SuVT/LBBB Yes No 2 major
and hypokinesis MRI: FF infiltration Inverted T waves VI-4 VPCS 13 000/24 h 3 minor
E: global dilatation
and hypokinesis
NL A: localised dyskinesia B:normal Inverted T waves Vl-4 SuVT/LBBB No No 1 major
E: no abnormalities MRI: FF infiltration 2 minor
LW A: not performed B: not performed Epsilon wave SuVT/LBBB NA Yes 2 major
E: global dilatation MRI: not performed Inverted T waves Vl-4 3 minor
and hypokinesis
MN A: localised dyskinesia, B: FF infiltration Inverted T waves Vl-4 NSuVT, VPCS No No 2 major
. mild global hypokinesis MRI:NA 1 minor
E: mild dilatation
SA A: limited dyskinesia B: myocarditis Epsilon wave SuVT/LBBB No No 2 major
E: prominent moderator A: FF infiltration Inverted T waves Vl-5 VPCs 53 000/24 h 3 minor
band
KM A: mild global dilatation, B: FF infiltration Inverted T waves Vl-4 VPCs/LBBB No Yes 1 major
regional hypokinesis MRI: FF infiltration 12000/24h 4 minor
E: mild global dilatation
KC A: not perfOrnied B: not performed Normal VPCS NA Yes MRI
E: mild global dilatation MRI: FF infiltration 2000/24 h 3 minor
MG A: localised dyskinesia B: FF infiltration Epsilon wave SuVT/LBBB Yes No 2 major
E: normal MRI: FF infiltration Inverted T waves Vl-4 3 minor
CK A: global dilatation B:hypertrophy Epsilon wave NsuVT/LBBB Yes Yes 2 major
and hypokinesis MRI: FF infiltration Inverted T waves Vl-4 VPCs 24 000/24 h 5 minor
E: global dilatation,
prominent MB
FB A: normal B: FF infiltration Epsilon wave NSuVT/LBBB No No 2 major
E: mild dilatation MRI: FF infiltration Inverted Twaves Vl-2 2 minor
TC A: limited dyskinesia, B: atrophy/ Normal SuVT/LBBB No No 2 major
mild global hypertrophy, 2 minor
hypokinesis FF infiltration
E: mild global dilatation, MRI: atrophy,
dilated RVOT, FF infiltration
trabecular disarray
CG A: not performed B:notperformed Borderline NSuVT NA Yes 1 major
E: mild dilatation, MRI: possible FF VPCS 3 500/24 h 3 minor
trabecular disarray infiltration,
RV wall thinning
• Confirmed at surgery and autopsy.
RV =right ventricle; SAECG =signal averaged ECG; A =angiography; E =echocardiography; RVOT = right ventrirular outflow tract; B =myocardial biopsy;
MRI = magnetic resonance imaging; FF = fibrofatty; A = not available; SuVT =sustained ventrirular tachycardia; LBBB =left bundle branch block
morphology; VPCS = ventrirular premature contractions; NSuVT = non-sustained ventrirular tachycardia.
induction was isoprenaline-dependent. Both ablation attempts
failed, probably because epicardial location of the substrate as
the fibrofatty infiltration documented on the MRI scan
involved the subepicardial area only.
Patient CK suffered from an extremely progressive course of
the disease and died due to a low cardiac output state 1 year
after his first symptom (syncope) and 3 months after a right
ventricular isolation for uncontrolled ventricular tachycardias.
His case will be discussed elsewhere.
The third patient (MN) died more than 4 years after the
diagnosis of ARVC/D was made. His ventricular tachycardia
was controlled on sotalol. He also suffered from arterial
hypertension and from atrial fibrillation that developed 2.4
years before his death. He was treated for pulmonary
tuberculosis and was admitted with pleural effusion to another
hospital 2 months before his death. We have failed to obtain
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Table ll. Oinical p.resentation and follow-up
Follow-up VT/ VT/VPCs Cardiac
Patient Age Sex (yrs) Presentation VT EPS EPS >1 morph LV failure Final outcome
SC 20 M 12.8 Exercise-induced VT Yes No No Yes Yes> No 'Controlled' on amiodarone-
recurrentbrealcllnough; ofslow vr
NL 43 M 5.3 Syncope during exertion Yes Yes Yes Yes Yes No No recurrences on amiodarone
LW 15 M 5.0 Palpitations Yes No No Yes NA No SCD (pro-arrhythmic effect of
propafenone?)
tMN 45 M 4.6 Palpitations, presyncope Yes No No NA Yes Yes/LV Died due to acute LV iailure
SA 29 M 2.5 Presyncope Yes Yes Yes Yes Yes No 'Controlled' on arnio&arone'
and beta-blocker (frequent
VPCs & NSuVT)
MC 30 M 2.2 Palpitations Yes Yes No No No No VT controlled on amiodarone
and atenolol*
KM 23 M 2.0 Chest pain, family history No Yes Yes§ Yes No No Asymptomatic on beta-
blocker
KC 15 M 2.0 Screening, family history No No No No No 0 Asymptomatic, no medication
CK 19 M 1.4 Syncope on exertion Yes Yes Yes Yes Yes Yes/ Died 3 months after RV
LV isolation due to low cardiac
output
FB 38 F 1.2 Palpitations on exertion Yes Yes Yes§ No No No Minimal symptoms on
arniodarone
TC 44 M 1.1 Palpitations, presyncope Yes Yes Yes Yes No No No breakthrough on sotalol
CC 22 M 0.5 Screening, family history No No No Yes No No Asymptomatic, no medication
• Angiographic LV ejection fraction 49%, echocardiographic LV ejection fraction nonnal.
t Patient suffered from pulmonary TB, arterial hypertension, and atrial fibrillation.
'" Patient suffered from arterial hypertension.
§ Non-sustained monomorphic ventricular tachycardia.
VT = sustained ventricular tachycardia documented; EPS = electrophysiological study perfonned; VTIEPS = ventricular tachycardia induced during
electrophysiological study; VPCS = ventricular premature contractions; morph = surface ECG morphology; LV = left ventricle or ventricular; M = male; F =
female; NA = not available; NSuVT = non-sustained ventricular tachycardia.
Table Ill. Treatment
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• Treatment was tenninated either because of a breakthrough of ventricular tachycardia or because of uncontrolled and symptomatic ventricular premature
contractions; phannacological treatment summarises drugs administered by different physicians since presentation.
t Patient was asymptomatic for 10 years without any treatment after original presentation with recurrent ventricular tachycardia.
'" Patients are asymptomatic - diagnosis established during family screening.














Drugs used (in chronological order»
Propranolol, mexiletine, arniodaronet
Disopyramide, sotalol, arniodarone
Mexiletine, procainarnide, disopyrarnide, sotalol, arniodarone, propafenone
Sotalol
Sotalol & mexiletine, arniodarone, arniodarone & atenolol
Acebutolol, sotalol, acebutolol
Propafenone, arniodarone, arniodarone & atenolol



















detailed data concerning the final period in that hospital;
however, he was transferred to us in pulmonary oedema with
severe left ventricular dysfunction and died a few hours after
arrival. There were no signs of ischaemia and the impairment
of left ventricular function was global without regional
differences.
Since none of the patients in this study died of non-cardiac
causes, the total cardiac mortality was 25%. Morbidity in
symptomatic patients was high as all of them had to be on
pharmacological treatment and all but one suffered from minor
symptoms.
Left ventricUlar involvement
Left ventricular dysfunction was observed in 5 of 10
symptomatic patients. Two deaths were consequences of left
ventricular failure, although causes other than ARVC/D cannot
be excluded in one of our patients who died. Old chronic
fibrotic changes in the left ventricle were found in the second
patient who died after right ventricular isolation.
DISCUSSION
Diagnosis
An appropriate diagnosis of ARVC/D has been restricted to the
academic cardiology unit, as the correct diagnosis was
suspected by the referring physician or cardiologist in only 1 of
the 12 cases reported here. The incidence of ARVC/D is not
known, but it has been shown to cause about 20% of sudden
deaths in people aged 20 - 40 years.' As a cause of sudden
death in this age group it may be as frequent as myocarditis,
pulmonary embolism and aortic dissection together. lO Despite
these facts ARVC/D is often overlooked. As shown in our
small group, the disease must be suspected in all racial groups.
The imbalance observed by ourselves is most likely owing to
varying access to health services rather than racial differences.
The incidence of familial disease (42%) in this study was
similar to findings of others/l and underlines the importance of
appropriate screening.
ARVC/D should be suspected in all patients presenting with
palpitations, unexplained syncope or ventricular tachycardia,
especially if they are young and their symptoms are related to
exertion or excitement. Ventricular arrhythmias present with
left bundle-branch morphology (Fig. 1), and echocardiography
documents either a normal heart or right ventricular
abnormalities. The differential diagnosis from benign right
ventricular outflow tract tachycardia in those without
significant right ventricular abnormalities may require
extensive investigation.
Evidence of structural and/ or functional abnormalities of the
right ventricle is crucial in establishing a diagnosis of ARVC/D.
Echocardiography is extremely important for primary
suspicion, and a detailed analysis of right ventricular anatomy
and function should be an organic part of echocardiographic
investigation of any young person with unexplained syncope
or ventricular tachycardia. However, angiography remained
the decisive method for establishment of right ventricular
anatomy and function in our patients. Echocardiographic
features 11 failed to discover limited right ventricular dyskinesia
that is highly specific for the diagnosis of ARVC/D13·l< inS
patients (NL, MN, SA, MG and KM). Lack of facilities for
dynamic assessment of MRl in our institution meant that it was
not possible to compare MRl with angiography.
Tissue characteristics are also crucial to the diagnosis. An
endomyocardial biopsy was performed in 8 patients and only 1
showed normal myocardium.l5 The presence of adipose cells or
tissue in endomyocardial samples was found in 5 patients,
while other abnormalities were documented in 2 (Table I). A
high number of positive findings among our patients was
probably related to our technique. We sampled not only the
septum, but also the apicoseptal and apical area of right
ventricle, i.e. in one of the locations of the 'triangle of
dysplasia'. No complications were observed. MRl was
extremely helpful once some experience was gained, and an
unequivocal finding of Tl-hyperintensity within the right
ventricular free wall, trabecules and / or interventricular septum
was typically found in patients who were diagnosed according
to the recommended criteria.' MRl was not used as a diagnostic
criterion in the reported group, with one exception. We did not
feel that a myocardial biopsy and/or angiography was
indicated in the completely asymptomatic patient KC.
Electrocardiographic findings were typical, as reported
before' (Fig. 1). Only one patient with an abnormal right
ventricle and ventricular tachycardia had a normal resting ECG
(TC). The presence of multiple morphologies of ventricular
tachycardia and / or frequent ventricular premature
contractions in 8 of 9 patients with documented ventricular
arrhythmia illustrates the complexity of arrhythmogenic
substrate and the difficulties that are inevitable if
radiofrequency catheter ablation and/ or limited arrhythmia
surgery are used in management.l~19
Treatment and prognosis
It is surprising that despite widely publicised results of trials
documenting risks of class IC anti-arrhythmic drugs in patients
with structural heart disease,'" 2 patients were started on
empirical propafenone before referral to Wentworth Hospital in
1995 and 1996 respectively. The use of class I anti-arrhythmic
drugs in ARVC/D is controversial. Monotherapy may be
extremely- dangerous;" however, class I anti-arrhythmic drugs
are still used in combination with class III drugs in some
countries, e.g. in the UK. At the end of follow-up occasional
palpitations were reported by all patients and were
documented as VPCs or short runs of non-sustained
ventricular tachycardia in some patients. Despite the fact that
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In general, class I anti-arrhythmic drugs should be avoided.
Beta-blockers are useful as they suppress adrenergic activity
that often triggers an arrhythmia; however, they should not be
used as monotherapy in a patient with ventricular tachycardia.
Sotalol and amiodarone are the mainstream drugs used in the
management of ARVC/D. If they fail, then all other available
therapeutic modalities such as catheter ablation, implantable
cardioverter / defibrillator, or surgery (right ventricular
isolation) must be considered in order to limit the arrhythmic
risk.
The mortality rate during 3.4 ±3.2 years was 25%. There was
one sudden death and two deaths due to left ventricular
failure. Although in one of them the cause of death was not
established beyond doubt, the fast progression of left
ventricular failure was similar to that seen in certain other
patients with ARVC/D.ll We believe that the cause of death in
the second patient was a latent left ventricular involvement
that manifested after right ventricular isolation. The relatively
poor prognosis in this series probably reflects underdiagnosis
and referral of only the most serious cases to a tertiary centre.
Mortality differs significantly among published studies
(Table IV). None of the published reports is really prospective
and the duration of follow-up varies. Furthermore, the
numbers reported are rather low, with one or two deaths
changing the statistics significantly. There may also be doubts
regarding the diagnosis in some cases, as the inclusion of
patients with idiopathic right ventricular outflow tract
tachycardia cannot be excluded. Despite the above it is obvious
that ARVC /D has a significant mortality. Moreover, the
morbidity is also very significant. It is difficult to analyse
morbidity from available literature; however, an attempt is
made in Table IV. Wherever possible we tried to establish the
number of patients who suffered from a recurrence of
ventricular tachycardia or cardiac failure during follow-up; this
was observed in 9 - 67% and 0 - 25% of cases respectively.
A very interesting aspect is temporary spontaneous
suppression of tachycardia. This was observed for 10 years in
our patient SC despite the fact that his right ventricular
cardiomyopathy / dysplasia had progressed significantly over
that period. A similar phenomenon of clinical ventricular
tachycardia disappearance was observed in 4 patients in
Leclercq and Coumel's report."
no complete control of symptoms has been achieved in
reported patients we feel that the empirical pharmacological
treatment was satisfactory, except in the case of patient LW. His
death was at least partly caused by poor compliance.
Psychological problems may have played a significant role, as
in the case of his sister who succumbed to the disease while
avoiding medical care and in the two suicides reported by
Marcus.' Psychological factors are especially prominent in
young patients from families that have lost other young
members to the disease.
'! r!, . ,.'-'--0'
Fig. 1 Typical ECG patterns of ARVC/D.
la. Ventricular tachycardia originating in the right ventricular
outflow tract. Broad QRS tachycardia (165 beats/min) with atypical
LBBB morphology (lateral precordial leads are not predominantly
positive) and right frontal electrical axis. There is no obvious A-V
dissociation. These ECG patterns may be documented in both benign
right ventricular outflow tract tachycardia and ARVC/D.
1b .Ventricular tachycardia originating in the right ventricular
apical area. Broad QRS tachycardia (150 beats/min) with LBBB
morphology and left frontal electrical axis. The right-to-Ieft septal
activation and left frontal axis suggest that the arrhythmia originates
in the right ventricular apical area, i.e. in one of the locations of the
'triangle of dysplasia'.
le. Sinus rhythm. Abnormalities typical ofARVC/D in the sinus
rhythm should be sought in precordial leads. The length of
depolarisation in Vl and V2 may be prolonged, as in this ECG,
and/or an abnormal terminal deflection of QRS (epsilon wave) may
be observed in leads Vl or V2. The most frequent repolarisation
changes are flat or inverted T waves in leads Vl-3 (V1-4 in this
recording).
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Table Iv. Review of follow-up of patients With ARVC!O (% in brackets adjusted for unavailable data)
Patients FU VT CHF LVF TPL Mortality Post
Authors (N) (yrs) recurrence (N) (N) !N) SD CF sw;gery Total
Blomstrom-Lundqvist + SabeP 15 15-28 10 (67) 3 (20) 0 0 2(13) 0 0 3 (20)
Leclercq + CoumeF' 58 8.8±72 NA NA 0 0 1 (7) 2 (3.5) 1(2) 5 (9)
Marcus et al.' 33 3.9- 8.4 3 (9) 7 (21) 1 (3) 0 2(6) 2 (6) 1 (3) 9*(27)
Lemery et al!' U 25-15 7 (58) 0 0 0 0 0 1 (8) 1 (8)
Wichter et al." 64 02-8.6 7 (11) 0 0 0 0 0 0 0
Canu et aI.a 22 10.7 6 (29) 4 (18) 0 0 3 (14) 0 0 5+ (23)
Daubert et al.'" 74 5.7±3.75 17 (67) NA NA 0 1 (1.4) 0 1 (1.4) 2 (2.7)
Pinamonti et aI.'Z7 43 1-23 NA 9 (21) 1 (2) 1 (2) 3 (7) 5 (12) 0 8 (I9)
Kullo et al.'" 20 1-15 3 (15) 5 (25) 0 2 (10) 2 (IO) 1 (5) 0 4 (20)
Thisreport 12 05-12.8 5 (42) 0 2 (16) 0 1 (8) 1 (8) 1 (8) 3 (25)
---
Total 353 2 -10.7 58 (19) 28 (13) 4 (1.4) 3 (0.8) 15 (4.2) 11 (3.1) 5 (1.4) 40 (11.3)
*One patient died during catheter ablation and two Committed suicide.
t Two patients were lost to follow-up.
FU = follow-up; VT = ventricular tachycardia; CHF = congestive heart failure; LVF =left ventricular failure; lPL =heart transplant; SD =sudden death; CF =
cardiac failure; NA =not available.
Patient CK had uncontrolled symptoms and succumbed to
the disease in less than 2 years. There is no doubt that the right
ventricular isolation played a significant role in the progression
of left ventricular dysfunction, which emphasises the need to
refine indications for different therapeutic approaches in
different subgroups. Although some reports on: right
ventricular isolation are very promising and show no
mortality," other results suggest that left ventricular
involvement may be a risk factor for arrhythmia surgery."
Death after arrhythmia surgery was reported in half the follow-
up studies analysed (Table N).
A better understanding of the pathobiology of the disease is
necessary as the differences among patients and reported
studies may be based on genetic differences29.30 or on different
insults causing and/ or triggering the progression of ARVC/D.
It is hoped that more understanding of ARVC/D will be
derived from prospective international registries (e.g. the US
arrhythmogenic right ventricular dysplasia registry, PO Box
245037, Tuscon, Arizona 85724-5037, USA).
In conclusion, ARVC/D occurs in the spectrum of cardiac
disorders among all groups of the South African population,
and all' indicated cases should be screened. Our experience
confirms that ARVC/D has a significant morbidity and
mortality and that more insight into the pathogenesis and
progression of the disease is necessary.
We thank the staff of our unit, especially the clinical
technologists and nurses who took part in investigation and
follow-up of patients with ARVC/D. Special thanks to Dr D D
Royston of the Department of Radiology, Wentworth Hospital,
Durban for analysing most of the MRI scans.
This paper was presented during the 21st Biennial Congress of
the Southern Africa Cardiac Society in Durban, 22 - 25 September
1998.
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RP Clauss, W M Giildenpfennig, H W Nel, M M Sathekge,
R R Venkannagari
A young semi-eomatose male patient was investigated using
99mTc hexamethyl-propylene amine oxime (""""rc HMPAO)
brain single photon emission computed tomography (SPECf)
before and after administration of the gamma-aminobutyric
acid (GABA) agonist zolpidem. It was observed that 15
minutes after application of the drug the patient awoke from
his semi-eomatose condition and remained awake for the
next 3 - 4 hours. When drug action subsided he returned to
his semi-eomatose state. Brain SPECf before drug application
showed large hypo-active areas in certain parts of the brain.
Brain SPECf after drug application showed a generalised
cortical activation relative to the cerebellum and a marked
and amplified activation of the areas that were hypo-active
before drug application.
s AfT Med /2000; 90: 68-72.
A semi-conscious patient was examined using 99mTc
hexamethyl-propylene amine oxime (99mTc HMPAO) brain
single photon emission computed tomography (SPECT) before
and after application of the. anti-insomnia drug zolpidem.
Consciousness may be defined as the ability to respond to
sensory stimuli and to have subjective experiences. Impaired
consciousness can range from mild suppression of
consciousness to complete coma.' Coma is a state of
unconsciousness from which the patient cannot be aroused.'
99mTc HMPAO is a lipophylic amine that crosses the blood-
brain barrier and is used as a marker of brain perrusion and
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